a3ar

A3AR antagonist 5 (Compound 16) acts as a selective antagonist for the human adenosine A3 receptor (human adenosine A3 receptor), with an affinity expressed as a pC value of 4.542 μM.

A3AR antagonist 1 is a potent and selective human A3adenosine receptor (AR) antagonist (Ki: 4.63) and has no affinity for the rat A3AR.

A3AR antagonist 2 is a potent antagonist of the human A3 adenosine receptor, exhibiting a Ki value of 4.54 nM.

A3AR modulator 1 (MRS8054), an orally active positive allosteric modulator (PAM) of the A3 adenosine receptor (A3AR) (Adenosine Receptor), significantly enhances the efficacy (E max) of Cl-IB-MECA-stimulated [35 S]GTPγS binding [1].

A3AR Agonist 1 (Compound 12), with a Ki of 25.8 nM, is a potent A3 adenosine receptor (A3AR) agonist that promotes β-arrestin2 recruitment with an effective concentration (EC50) of 5.17 nM. It serves as a research tool in various pathological conditions, including inflammatory diseases, ischemia, cancer, neuropathic pain, and liver diseases [1].

Compound 19, a selective A3 Adenosine Receptor (A3AR) agonist (K i : 22.1 nM), effectively stimulates β-arrestin2 recruitment with an EC 50 value of 4.36 nM. This compound is utilized in research pertaining to inflammatory diseases, ischemia, cancer, neuropathic pain, liver diseases, and other chronic conditions [1].

Compound 15A, also known as A3AR agonist 3, acts as an agonist for the A3 adenosine receptor (A3AR), exhibiting K_i and EC_50 values of 2.27 nM and 0.20 nM for hA3 and cAMP, respectively. This compound is utilized in neuroinflammation research [1].

A3AR agonist 4, an A3 adenosine receptor (A3AR) agonist, exhibits an inhibitory affinity (K i) of 1.24 nM for hA3AR and dampens cAMP production with an EC 50 value of 0.17 nM. It is utilized in the study of inflammation and pain [1].

Compound 6b, also known as A3AR agonist 5, serves as an A3 adenosine receptor (A3AR) activator and exhibits potent EC50 and Ki values of 0.14 nM and 6.36 nM for cAMP and hA3, respectively. This compound is primarily utilized in research related to pain and inflammation [1].

hA3AR agonist 2 is a potent activator of A3AR, with a Ki value of 3.5 nM.

hA3AR agonist 1 is a potent human A3 adenosine receptor (hA3AR) agonist with a Ki of 2.40 nM.

N6-(2-Phenylethyl)adenosine (N6-Phenethyladenosine) is an adenosine derivative and adenosine receptor agonist with Ki values of 11.8 nM for rat A1 receptors and 30.1 nM for human A1 receptors.

N6-Ethyladenosine, an adenosine derivative, acts as an agonist of Adenosine receptors (hA1AR and hA3AR) with Ki values of 4.9 nM and 4.7 nM, respectively.

Namodenoson (2-Cl-IB-MECA) is an adenosine A3 receptor agonist.

MRS1177 is an effective and selective antagonist of the human Adenosine A3 receptor (hA3AR) (Ki: 0.3 nM).

MRS1186 is an effective and selective antagonist of the human Adenosine A3 receptor (Ki: 7.66 nM).

I-AB-MECA is a significant radioactive ligand used in the study of the A3 adenosine receptor (A3AR).

PSB-10 hydrochloride is a human adenosine A3 receptor antagonist.

A2AAR HDAC-IN-2 is a potent dual A2AAR HDAC inhibitor with good affinity for A2AAR (Ki: 10.3 nM) and effective HDAC1 inhibition (IC50: 18.5 nM). A2AAR HDAC-IN-2 is applicable in anti-tumour studies.

MRS542 is a A3AR antagonist as found by cyclic AMP assays, and a partial agonist as found by beta-arrestin translocation. LUF6000 is responsible for the partial agonist nature of MRS542.

DPTN dihydrochloride is a potent and selective A3AR antagonist with Ki values of 1.65, 9.61 and 8.53 nM in human, mouse and rat, respectively.

MRS 5980, an A3AR agonist with a K i value of 0.7 nM, exhibits oral activity [1].

MRS5663 (Compound 3a), an A3AR agonist, exhibits an EC50 value of 5.62 nM in β-arrestin2 recruitment assays. This compound demonstrates cytoprotective effects in skeletal muscle ischemia-reperfusion injury claudication models.

MRS8028 is an agonist for the A3 adenosine receptor (A3AR), binding with a Ki of 2.44 nM to hA3AR. The compound demonstrates potential in alleviating ischemic and inflammatory diseases.